文献速递癫痫

[18F]DPA-714 PET 成像在耐药性局灶性癫痫患者术前评估中的应用

[18F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy.
PubMed 文献 · Neurology · 2023-09-25

本研究纳入23例耐药性局灶性癫痫患者,在完成第一阶段术前评估后比较[18F]DPA-714 PET与[18F]FDG PET定位致痫区的价值。结果显示[18F]DPA-714 PET在显示异常和提供额外定位信息方面均显著优于[18F]FDG PET,尤其在[18F]FDG PET正常者中全部显示异常。

要点

  • 视觉分析显示[18F]DPA-714 PET 显示异常率95.7%,显著高于[18F]FDG PET的56.5%(p=0.022)。
  • [18F]DPA-714 PET 提供额外致痫区定位信息率65.2%,显著高于[18F]FDG PET的17.4%(p=0.019)。
  • 10例[18F]FDG PET正常的患者中,[18F]DPA-714 PET均显示异常。

核心结论

  • [18F]DPA-714 PET成像为耐药性局灶性癫痫患者的术前评估提供了有价值的信息。
  • TSPO PET可能成为帮助定位致痫区的额外工具,尤其在[18F]FDG PET阴性的患者中。

研究设计与样本

  • 研究比较了23例已完成第一阶段术前评估的耐药性局灶性癫痫患者的[18F]FDG与[18F]DPA-714 PET图像,采用定性视觉分析和定量分析(体素及区域水平)。
  • 视觉分析由2名对致痫区位置不知情的经验丰富临床医生独立审阅[18F]DPA-714 PET图像。
  • 试验注册号Eudract 2017-003381-27,首例患者纳入日期为2018年9月24日。
  • 证据等级:本研究提供IV级证据,关于[18F]DPA-714 PET与[18F]FDG PET在识别接受第一阶段术前评估的难治性癫痫患者致痫区中的效用。

主要发现

  • 视觉分析中,[18F]DPA-714 PET显示异常的比例为95.7%,[18F]FDG PET为56.5%(p=0.022),前者显著更准确。
  • 视觉分析中,[18F]DPA-714 PET提供额外信息以细化致痫区定位的比例为65.2%,[18F]FDG PET为17.4%(p=0.019)。
  • 10例[18F]FDG PET正常的患者中,使用[18F]DPA-714 PET均显示异常。
  • 体素分析中,[18F]DPA-714较[18F]FDG更有效地揭示与致痫区假设定位一致的簇(87.0% vs 39.1%,p=0.019)。
  • 视觉分析中23例患者有14例出现非相关结合,体素分析中23例患者有9例出现非相关结合。

关键数值与推荐

  • 视觉分析显示异常率:[18F]DPA-714 PET 95.7% vs [18F]FDG PET 56.5%(p=0.022)。
  • 视觉分析提供额外致痫区定位信息率:[18F]DPA-714 PET 65.2% vs [18F]FDG PET 17.4%(p=0.019)。
  • 体素分析中簇定位与致痫区假设一致率:[18F]DPA-714 PET 87.0% vs [18F]FDG PET 39.1%(p=0.019)。

临床怎么用

  • 原文结论指出[18F]DPA-714 PET成像为耐药性局灶性癫痫患者的术前评估提供了有价值的信息。
  • 原文结论认为TSPO PET可能成为帮助定位致痫区的额外工具,尤其在[18F]FDG PET阴性的患者中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Translocator protein 18 kDa (TSPO) PET imaging is used to monitor glial activation. Recent studies have proposed TSPO PET as a marker of the epileptogenic zone (EZ) in drug-resistant focal epilepsy (DRFE). This study aims to assess the contributions of TSPO imaging using [18F]DPA-714 PET and [18F]FDG PET for localizing the EZ during presurgical assessment of DRFE, when phase 1 presurgical assessment does not provide enough information. METHODS: We compared [18F]FDG and [18F]DPA-714 PET images of 23 patients who had undergone a phase 1 presurgical assessment, using qualitative visual analysis and quantitative analysis, at both the voxel and the regional levels. PET abnormalities (increase in binding for [18F]DPA-714 vs decrease in binding for [18F]FDG) were compared with clinical hypotheses concerning the localization of the EZ based on phase 1 presurgical assessment. The additional value of [18F]DPA-714 PET imaging to [18F]FDG for refining the localization of the EZ was assessed. To strengthen the visual analysis, [18F]DPA-714 PET imaging was also reviewed by 2 experienced clinicians blind to the EZ location. RESULTS: The study included 23 patients. Visual analysis of [18F]DPA-714 PET was significantly more accurate than [18F]FDG PET to both, show anomalies (95.7% vs 56.5%, p = 0.022), and provide additional information to refine the EZ localization (65.2% vs 17.4%, p = 0.019). All 10 patients with normal [18F]FDG PET had anomalies when using [18F]DPA-714 PET. The additional value of [18F]DPA-714 PET seemed to be greater in patients with normal brain MRI or with neocortical EZ (especially if insula is involved). Regional analysis of [18F]DPA-714 and [18F]FDG PET provided similar results. However, using voxel-wise analysis, [18F]DPA-714 was more effective than [18F]FDG for unveiling clusters whose localization was more often consistent with the EZ hypothesis (87.0% vs 39.1%, p = 0.019). Nonrelevant bindings were seen in 14 of 23 patients in visual analysis and 9 patients of 23 patients in voxel-wise analysis. DISCUSSION: [18F]DPA-714 PET imaging provides valuable information for presurgical assessments of patients with DRFE. TSPO PET could become an additional tool to help to the localization of the EZ, especially in patients with negative [18F]FDG PET. TRIAL REGISTRATION INFORMATION: Eudract 2017-003381-27. Inclusion of the first patient: September 24, 2018. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the utility of [18F]DPA-714 PET compared with [18F]FDG PET in identifying the epileptic zone in patients undergoing phase 1 presurgical evaluation for intractable epilepsy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cheval M, Rodrigo S, Taussig D, et al. [18F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy. Neurology. 2023. PMID: 37748889. doi:10.1212/WNL.0000000000207811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。